—>
Main Menu

Progress for drugs firm

PharmaKrysto secures licensing deal in US

Julian HowellEarly stage Scottish drugs company PharmaKrysto,has completed an exclusive global licensing deal with Rutgers University in New Jersey for a potentially revolutionary compound to treat people suffering from a kidney disease.

PK10 is a treatment for cystinuria is an inherited disease that causes large, painful and debilitating crystals of amino acid to form in the kidneys.

Edinburgh-based PharmaKrysto has also been granted a key clearance by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).  

The company is now receiving support for a fundraising round to prepare for patient trials.

Chief executive Julian Howell said: “These three events represent the achievement of major milestones for PharmaKrysto as we seek to develop this exciting new treatment for people with cystinuria.”



Leave a Reply

Your email address will not be published. Required fields are marked as *

*

This site uses Akismet to reduce spam. Learn how your comment data is processed.